Five Prime licensing deal propels it into hot antibody-drug conjugate space
November 05, 2013 at 18:24 PM EST
A Swiss company will use antibodies licensed from Five Prime Therapeutics Inc. to develop cancer drugs in one of the biotech industry's hottest areas, antibody-drug conjugates...
